JP2017530176A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530176A5
JP2017530176A5 JP2017518804A JP2017518804A JP2017530176A5 JP 2017530176 A5 JP2017530176 A5 JP 2017530176A5 JP 2017518804 A JP2017518804 A JP 2017518804A JP 2017518804 A JP2017518804 A JP 2017518804A JP 2017530176 A5 JP2017530176 A5 JP 2017530176A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
group
independently selected
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518804A
Other languages
English (en)
Japanese (ja)
Other versions
JP6820254B2 (ja
JP2017530176A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/091614 external-priority patent/WO2016055028A1/en
Publication of JP2017530176A publication Critical patent/JP2017530176A/ja
Publication of JP2017530176A5 publication Critical patent/JP2017530176A5/ja
Application granted granted Critical
Publication of JP6820254B2 publication Critical patent/JP6820254B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518804A 2014-10-10 2015-10-10 治療用化合物およびその使用 Expired - Fee Related JP6820254B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014088315 2014-10-10
CNPCT/CN2014/088315 2014-10-10
PCT/CN2015/091614 WO2016055028A1 (en) 2014-10-10 2015-10-10 Therapeutic compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2017530176A JP2017530176A (ja) 2017-10-12
JP2017530176A5 true JP2017530176A5 (enExample) 2018-11-22
JP6820254B2 JP6820254B2 (ja) 2021-01-27

Family

ID=55652608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518804A Expired - Fee Related JP6820254B2 (ja) 2014-10-10 2015-10-10 治療用化合物およびその使用

Country Status (5)

Country Link
US (1) US10206931B2 (enExample)
EP (1) EP3204360B1 (enExample)
JP (1) JP6820254B2 (enExample)
CN (1) CN107108512B (enExample)
WO (1) WO2016055028A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077375A1 (en) * 2014-11-10 2016-05-19 Genentech, Inc. Bromodomain inhibitors and uses thereof
SG11201806302RA (en) 2016-02-05 2018-08-30 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
JP7160688B2 (ja) * 2016-05-24 2022-10-25 ジェネンテック, インコーポレイテッド Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
CA3031525A1 (en) 2016-07-25 2018-02-01 Epizyme, Inc. Crebbp related cancer therapy
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN107325092B (zh) * 2017-08-07 2021-01-08 山东鲁宁药业有限公司 一种阿奇沙坦的制备新工艺
CN107643405B (zh) * 2017-09-19 2020-07-17 上海市肺科医院 一种基于自身抗体检测的肺癌诊断试剂盒及其应用
WO2019070742A1 (en) * 2017-10-03 2019-04-11 Sidecar Therapeutics, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITORS COMPOUNDS
AU2019245403B2 (en) 2018-03-29 2025-02-06 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
US10899769B2 (en) 2018-04-06 2021-01-26 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
WO2020173440A1 (en) * 2019-02-27 2020-09-03 Cullgen (Shanghai), Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
CA3131383A1 (en) * 2019-02-27 2020-09-03 Constellation Pharmaceuticals, Inc. P300/cbp hat inhibitors and methods for their use
US20230086702A1 (en) 2019-04-18 2023-03-23 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a]pyridine derivatives and use thereof
CN114007652A (zh) 2019-06-18 2022-02-01 达纳-法伯癌症研究公司 小分子靶向溴/乙酰蛋白及其用途
CN110170052B (zh) * 2019-06-21 2020-07-10 复旦大学 Cbp-p300抑制剂在肠道损伤疾病中的应用
TW202120095A (zh) * 2019-08-05 2021-06-01 美商美國禮來大藥廠 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
AU2021259814B2 (en) * 2020-04-25 2023-09-28 Pharmablock Sciences (Nanjing), Inc. CBP/EP300 inhibitor and use thereof
AU2021270458A1 (en) 2020-05-13 2022-11-10 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis
TW202210472A (zh) 2020-06-05 2022-03-16 美商奇奈特生物製藥公司 纖維母細胞生長因子受體激酶之抑制劑
US20230250088A1 (en) * 2020-07-15 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20240270695A1 (en) * 2021-01-12 2024-08-15 Chengdu Anticancer Bioscience Ltd Compounds, compositions and methods of treating disorders
EP4326712A4 (en) * 2021-04-21 2025-03-05 The Regents of The University of California COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
WO2022231262A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제의 제조 방법
WO2023088420A1 (en) * 2021-11-19 2023-05-25 Chengdu Anticancer Bioscience, Ltd. 1h-benzo[b]azepin-2(3h)-one compounds, compositions and methods of treating cancer
IL314082A (en) 2022-01-12 2024-09-01 Denali Therapeutics Inc Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3203952A (en) * 1962-12-04 1965-08-31 Upjohn Co Chloromethylsulfonamides of cyclic diamines
US3361750A (en) * 1963-03-21 1968-01-02 Squibb & Sons Inc Benzothiazepines
DE3800386A1 (de) * 1988-01-09 1989-07-20 Bayer Ag Verfahren zur herstellung von benzothiazepinon-derivaten
WO2006051851A1 (ja) * 2004-11-10 2006-05-18 Wakamoto Pharmaceutical Co., Ltd. 2,3,4,5-テトラヒドロ-1h-1,5-ベンゾジアゼピン誘導体、及び、医薬組成物
DE102006051796A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
EP2705039B1 (en) * 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類

Similar Documents

Publication Publication Date Title
JP2017530176A5 (enExample)
JP2019516757A5 (enExample)
JP2019516759A5 (enExample)
JP2017533250A5 (enExample)
JP2017537100A5 (enExample)
JP2017526696A5 (enExample)
JP2018501287A5 (enExample)
JP2017533249A5 (enExample)
JP2018510851A5 (enExample)
JP2017530984A5 (enExample)
JP2017533248A5 (enExample)
JP2017525740A5 (enExample)
JP2018507191A5 (enExample)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2016529312A5 (enExample)
JP2016510748A5 (enExample)
JP2017121233A5 (enExample)
JP2016513137A5 (enExample)
JP2014506601A5 (enExample)
JP2012526143A5 (enExample)
JP2010522194A5 (enExample)
JP2016503799A5 (enExample)
JP2016525097A5 (enExample)
JP2016506916A5 (enExample)
JP2011510080A5 (enExample)